Acute Myeloid Leukemia (AML)

The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator

Original Publication Date
Article Source
External Web Content
PURPOSE: Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and…

ASH 2021 Updates: MDS and Secondary AML

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Presenter(s)
Elizabeth Griffiths, MD
In this webinar, Dr. Elizabeth Griffiths discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and secondary AML. These studies were presented at the American Society of Hematology (ASH) 2021 meeting in Atlanta, GA. Research…

Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes

Original Publication Date
Article Source
External Web Content
Key Points Structural racism (SR) assessed by census tract variables accounts for nearly all Black-white and Hispanic-white disparity in AML survival. Structural Racism is a stronger mediator of survival disparities than molecular features, co-morbidities, healthcare access and…

What's My Doctor Thinking? Treating Secondary AML

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Presenter(s)
Firas El Chaer, MD
In this webinar, Dr. Firas El Chaer discusses the diagnosis of secondary AML and how treatment options are decided . Secondary acute myeloid leukemia (AML) refers to a condition in patients who have had prior myelodysplasia (MDS), myeloproliferative disorder, or aplastic anemia…

Firas El Chaer, MD

Institution
University of Virginia
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Firas El Chaer, MD, is an assistant professor of medicine who specializes in hematology and oncology. His clinical areas of interest are acute leukemia, chronic leukemia, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, clonal hematopoiesis and blood disorders. His research focuses on improving outcomes for acute leukemia in adults by focusing on targeted therapies and overcoming resistance mechanisms. Dr. El Chaer attended medical school at the University of Balamand in Beirut, Lebanon, and completed his internal medicine residency at the Icahn School of Medicine at

Seeing Cancer From All Sides: Richard M. Stone Is Giant of Cancer Care in Leukemia

Original Publication Date
Article Source
External Web Content
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research. Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15…

Science Simplified: What is a Natural History Study?

Original Publication Date
Article Source
External Web Content
Want to learn about scientific topics without needing a PhD? Check out the Science Simplified blog from TESS Research Foundation! Dr. Tanya Brown, PhD, works with researchers to make science accessible and empower rare disease community members with scientific knowledge. Dr…

Genetic Testing for Bone Marrow Failure Diseases

Thumbnail for video Watch Now

Topic(s)
Living Well with Bone Marrow Failure
Managing Your Treatment
Presenter(s)
Jadee Neff, M.D., Ph.D., FCAP
In this webinar, Dr. Jadee Neff discusses how genetic testing used in the diagnostic process, how it can help identify possible causes of disease that inform decisions regarding appropriate therapies, identify potential donors for bone marrow transplant, and potential risk for…

Clinical Trials and Children

Until recently, children were rarely included in studies of medical treatments. As a result, much is still unknown about how children respond to drugs, some biologics (such as gene therapy) and medical devices. According to the U.S. Food and Drug Administration (FDA), only 20-30% of approved drugs have actually been labeled for use in children.

Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.